摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-哌啶-4-甲基-苯甲酰胺 | 333795-12-3

中文名称
4-哌啶-4-甲基-苯甲酰胺
中文别名
4-(哌啶-4-基甲基)苯甲酰胺
英文名称
4-(piperidin-4-ylmethyl)benzamide
英文别名
4-(piperidin-4-ylmehyl)benzamide;4-(4-Piperidinylmethyl)benzamide;4-(4-piperidylmethyl)benzamide
4-哌啶-4-甲基-苯甲酰胺化学式
CAS
333795-12-3
化学式
C13H18N2O
mdl
MFCD11974855
分子量
218.299
InChiKey
OIYNIIJKRNGHJM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    400.6±33.0 °C(Predicted)
  • 密度:
    1.094±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    55.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:b18de8986ffa031ea8e391040cb124f4
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of a Piperidine-4-carboxamide CCR5 Antagonist (TAK-220) with Highly Potent Anti-HIV-1 Activity
    摘要:
    We incorporated various polar groups into previously described piperidine-4-carboxamide CCR5 antagonists to improve their metabolic stability in human hepatic microsomes. Introducing a carbamoyl group into the phenyl ring of the 4-benzylpiperidine moiety afforded the less lipophilic compound 5f, which possessed both high metabolic stability and good inhibitory activity of HIV-1 envelope-mediated membrane fusion (IC50 = 5.8 nM). Further optimization to increase potency led to the discovery of 1-acetyl-N-{3-[4-(4-carbamoylbenzyl) piperidin-1-yl]propyl}-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide (5m, TAK-220), which showed high CCR5 binding affinity (IC50 = 3.5 nM) and potent inhibition of membrane fusion (IC50 = 0.42 nM), as well as good metabolic stability. Compound 5m strongly inhibited the replication of CCR5-using HIV-1 clinical isolates in human peripheral blood mononuclear cells (mean EC50 = 1.1 nM, EC90 = 13 nM) and exhibited a good pharmacokinetic profile in monkeys (BA = 29%). This compound has been chosen as a clinical candidate for further development.
    DOI:
    10.1021/jm051034q
  • 作为产物:
    描述:
    4-(4-piperidylidenemethyl)benzamide 在 palladium 10% on activated carbon 氢气 作用下, 以 四氢呋喃 为溶剂, 反应 1.0h, 以98.7%的产率得到4-哌啶-4-甲基-苯甲酰胺
    参考文献:
    名称:
    EP1359145
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2001025200A1
    公开(公告)日:2001-04-12
    A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物式为(I)(其中R1是氢原子,可被取代的碳氢基团,可被取代的非芳香杂环基团,R2是可被取代的碳氢基团,可被取代的非芳香杂环基团,或R1和R2可以与A一起结合形成可被取代的杂环基团;A是N或N+ -R5 • Y-(R5是碳氢基团;Y-是反离子);R3是可被取代的环烃基团或可被取代的杂环基团;n为0或1;R4是氢原子,可被取代的碳氢基团,可被取代的杂环基团,可被取代的烷氧基,可被取代的芳氧基,或可被取代的氨基,E是可被除氧基以外的基取代的二价脂肪烃基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团;前提是当G2是OCO时,J是甲基,当另一个是键时,其中一个不是键,当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,并可用于人类各种HIV感染疾病(例如艾滋病)的治疗或预防。
  • Process for preparation of benzylpiperidine compounds
    申请人:Miki Shokyo
    公开号:US20060094877A1
    公开(公告)日:2006-05-04
    According to the process as shown in the following scheme having a step for reacting Compound (I) with Compound (II) to produce Compound (III), benzylpiperidine compounds useful as synthesis starting materials of pharmaceutical agents, agricultural chemicals and the like can be produced conveniently by a short step: wherein R 1 is a hydrogen atom or an amino-protecting group, R 2 is a hydrogen atom, a hydrocarbon group optionally having substituents, an alkoxy group optionally having substituents or a heterocyclic group optionally having substituents, and R 3 is a lower alkyl group.
    根据下图所示的过程,其中包含将化合物(I)与化合物(II)反应以产生化合物(III)的步骤,可以通过简短的步骤方便地生产用作制药剂、农业化学品等综合起始材料的苯甲基哌啶化合物:其中R1是氢原子或氨基保护基,R2是氢原子、烃基(可选取代基)、烷氧基(可选取代基)或杂环基(可选取代基),R3是较低的烷基基团。
  • Benzamide derivatives
    申请人:Imazaki Naonori
    公开号:US20050182040A1
    公开(公告)日:2005-08-18
    A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R 1 , R 2 , R 3 and R 4 , which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na + /H + exchange transport system caused by the Rho kinase inhibition, for example, hypertension.
    一种由公式(1)表示的化合物:其中X是单键或取代或未取代的较低烷基链;Z是饱和或不饱和的单环烃基环或类似物;而每个R1、R2、R3和R4,可以相同也可以不同,是氢原子、卤素原子、硝基、氰基、羧基、取代或未取代的烷基或类似物,该化合物的前药,或该化合物或前药的药学上可接受的盐具有抑制Rho激酶的作用,因此可用于治疗因抑制Rho激酶而预计疾病的发病率得到改善的疾病,例如高血压,并且由于Rho激酶抑制所引起的Na+/H+交换转运系统的抑制等二次效应。
  • Cyclic amine compounds as CCR5 antagonists
    申请人:——
    公开号:US20030114443A1
    公开(公告)日:2003-06-19
    A compound of formula (I) (wherein R 1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R 2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R 1 and R 2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N + —R 5 .Y − (R 5 is a hydrocarbon group; Y − is a counter anion); R 3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R 4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G 1 is a bond, CO or SO 2 ; G 2 is CO, SO 2 , NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C 1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G 2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G 1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物的式子 (I) (其中R1是氢原子、可以被取代的碳氢基团、可以被取代的非芳香族杂环基团,R2是可以被取代的碳氢基团、可以被取代的非芳香族杂环基团,或R1和R2可以与A结合形成可以被取代的杂环基团;A是N或N+—R5.Y−(R5是碳氢基团;Y−是反离子);R3是可以被取代的环烃基团或可以被取代的杂环基团;n为0或1;R4是氢原子、可以被取代的碳氢基团、可以被取代的杂环基团、可以被取代的烷氧基、可以被取代的芳氧基,或可以被取代的氨基团;E是可以被取代的二价脂肪烃基团,该基团可以被除氧基团外的其他基团取代;G1是键、CO或SO2;G2是CO、SO2、NHCO、CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是键或可以被取代的二价C1-3脂肪基团;但是当G2是OCO时,J是甲基;当Q和R中的一个是键时,另一个不是键;当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,可以用于治疗或预防人类各种HIV感染性疾病(例如艾滋病)。
  • PROCESS FOR PREPARATION OF BENZYLPIPERIDINE COMPOUNDS
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1359145A1
    公开(公告)日:2003-11-05
    According to the process as shown in the following scheme having a step for reacting Compound (I) with Compound (II) to produce Compound (III), benzylpiperidine compounds useful as synthesis starting materials of pharmaceutical agents, agricultural chemicals and the like can be produced conveniently by a short step: wherein R1 is a hydrogen atom or an amino-protecting group, R2 is a hydrogen atom, a hydrocarbon group optionally having substituents, an alkoxy group optionally having substituents or a heterocyclic group optionally having substituents, and R3 is a lower alkyl group.
    根据下图所示的工艺,其中有一个步骤是使化合物 (I) 与化合物 (II) 反应生成化合物 (III),根据该工艺,可以通过一个简短的步骤方便地生产出苄基哌啶化合物,该化合物可用作药剂、农药等的合成起始原料: 其中,R1 是氢原子或氨基保护基,R2 是氢原子、可选带取代基的烃基、可选带取代基的烷氧基或可选 带取代基的杂环基,R3 是低级烷基。
查看更多